Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR

The prostate is an androgen‐regulated organ and polymorphisms in genes involved in testosterone synthesis, in particular, SRD5A2 (A49T and V89L variants), CYP17 (MspAI variant), and the AR (CAG, GGC repeats), represent candidate risk factors for prostate cancer incidence and aggressiveness.

[1]  J. Stanford,et al.  A polymorphism in the CYP17 gene and risk of prostate cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[2]  S. Piantadosi,et al.  Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  T. Rebbeck,et al.  Association of SRD5A2 genotype and pathological characteristics of prostate tumors. , 2000, Cancer research.

[4]  R. Kittles,et al.  Cyp17 promoter variant associated with prostate cancer aggressiveness in African Americans. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[5]  N. Chamberlain,et al.  The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. , 1994, Nucleic acids research.

[6]  G. Coetzee,et al.  The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. , 1995, Cancer research.

[7]  P. Kantoff,et al.  The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Marberger,et al.  A polymorphism in the CYP17 gene is associated with prostate cancer risk , 2000, International journal of cancer.

[9]  J. Ioannidis,et al.  Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[10]  M. Schoenberg,et al.  Androgen-receptor gene structure and function in prostate cancer , 2004, World Journal of Urology.

[11]  J. Brooks,et al.  Polymorphisms in the androgen receptor and type II 5α‐reductase genes and prostate cancer prognosis , 2002, The Prostate.

[12]  E. Lander,et al.  Androgen Metabolism and Prostate Cancer: Establishing a Model of Genetic Susceptibility , 1998, European Urology.

[13]  W. Vogel,et al.  (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French–German population , 1999, European Journal of Human Genetics.

[14]  J. Little,et al.  Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. , 1994, Human molecular genetics.

[15]  R. Eeles,et al.  Androgen receptor polymorphisms: Association with prostate cancer risk, relapse and overall survival , 1999, International journal of cancer.

[16]  P. Kantoff,et al.  The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[17]  K. Cooney,et al.  The polymorphic exon 1 androgen receptor CAG repeat in men with a potential inherited predisposition to prostate cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[18]  Jack A. Taylor,et al.  Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). , 1999, Carcinogenesis.

[19]  Ahmedin Jemal,et al.  Annual Report to the Nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden , 2002, Cancer.

[20]  G. Rouleau,et al.  Reduced transcriptional regulatory competence of the androgen receptor in X–linked spinal and bulbar muscular atrophy , 1993, Nature genetics.

[21]  T. Rebbeck.  Inherited genotype and prostate cancer outcomes. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[22]  J. Trachtenberg,et al.  V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. , 2001, Urology.

[23]  N. Makridakis,et al.  Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II. , 2000, Pharmacogenetics.

[24]  J. Witte,et al.  CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[25]  Ruth Etzioni,et al.  Androgen receptor polymorphisms and the incidence of prostate cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[26]  H. Scher,et al.  Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. , 1996, The Journal of clinical endocrinology and metabolism.

[27]  L. Sobin,et al.  TNM classification of malignant tumors, fifth edition (1997) , 1997, Cancer.

[28]  T H Beaty,et al.  Family history and the risk of prostate cancer , 1990, The Prostate.

[29]  G. Coetzee,et al.  Does the racial‐ethnic variation in prostate cancer risk have a hormonal basis? , 1995 .

[30]  Å. Borg,et al.  CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk , 1999, British Journal of Cancer.

[31]  P. Febbo,et al.  The V89L Polymorphism in the 5α-Reductase Type 2 Gene and Risk of Prostate Cancer , 1999 .

[32]  S. Narod,et al.  The impact of family history on early detection of prostate cancer , 1995, Nature Medicine.

[33]  P. Kantoff,et al.  The androgen receptor gene GGN microsatellite and prostate cancer risk. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[34]  C. Wadelius,et al.  Prostate cancer associated with CYP17 genotype. , 1999, Pharmacogenetics.

[35]  M. Pike,et al.  A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. , 1997, Cancer research.

[36]  T. Habuchi,et al.  Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. , 2000, Cancer research.

[37]  L Pinsky,et al.  Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies. , 1995, Human molecular genetics.

[38]  P. Hartge,et al.  Excluding controls: misapplications in case-control studies. , 1984, American journal of epidemiology.

[39]  T. Katoh,et al.  Impact of genetic polymorphisms of 17‐hydroxylase cytochrome P‐450 (CYP17) and steroid 5α‐reductase type II (SRD5A2) genes on prostate‐cancer risk among the Japanese population , 2001, International journal of cancer.

[40]  J. Johansson,et al.  5alpha-reductase 2 polymorphisms as risk factors in prostate cancer. , 2002, Pharmacogenetics.

[41]  M. Frydenberg,et al.  A case–control study of the androgen receptor gene CAG repeat polymorphism in Australian prostate carcinoma subjects , 2001, Cancer.

[42]  M. Pike,et al.  Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA , 1999, The Lancet.

[43]  G. Coetzee,et al.  Evidence of an X-linked or recessive genetic component to prostate cancer risk , 1995, Nature Medicine.

[44]  J. Stanford,et al.  Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. , 1997, Cancer research.

[45]  F. Ghadessy,et al.  Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. , 1997, The Journal of clinical endocrinology and metabolism.

[46]  J. Schleutker,et al.  A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland , 2001, British Journal of Cancer.

[47]  O. Cussenot,et al.  Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways , 2001, Cancer.

[48]  C. Poole.  Controls who experienced hypothetical causal intermediates should not be excluded from case-control studies. , 1999, American journal of epidemiology.

[49]  J. Witte,et al.  Asymptotic bias and efficiency in case-control studies of candidate genes and gene-environment interactions: basic family designs. , 1999, American journal of epidemiology.

[50]  S. Coughlin,et al.  A review of genetic polymorphisms and prostate cancer risk. , 2002, Annals of epidemiology.

[51]  G. Coetzee,et al.  Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. , 1997, Journal of the National Cancer Institute.